Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Sareum update reveals extent of progress made by co's licence partner

Sareum has partnered with Sierra Oncology to advance the company's Checkpoint kinase 1 inhibitor
cancer cells from taken by an electron microscope
The company's lead drug, SRA737, has the potential to treat multiple cancers

Interim results from Sareum Holdings PLC (LON:SAR) charted a period of significant progress for the cancer drug developer and its licence partner Sierra Oncology.

Sareum said Sierra had made “strong progress” with the two clinical studies of its Checkpoint kinase 1, or Chk1 inhibitor, SRA737.

This has led to a significant expansion of the development programme going into 2018.

Last month Sierra said the Phase I portion of the Phase I/II clinical trial of SRA737 as a single cancer therapy was in the final stages.

Phase II group expanded

Encouragingly, Phase II has been expanded to include more patients across six cancer indications and at a larger number of clinical sites.

In parallel, Sierra is running a Phase I/II trial using SRA737 in combination with low-dose Gemcitabine, one of the most commonly prescribed chemotherapies.

Phase II of this trial is expected to get underway in the second-quarter, with the enrolment of 80 genetically selected patients across four indications.

Sierra plans to start an early-stage clinical study of SRA737 in combination with a PARP inhibitor in the final quarter of the year. PARP inhibitors prevent cancer cells repairing themselves.

Chief executive, Dr Tim Mitchell, said he had been “encouraged” by Sierra’s progress and by the potential of SRA737 to treat multiple cancers.

“We look forward to initial results from the innovative clinical trials expected in the fourth quarter of 2018 and further programme updates during the year,” he added.

Separately, Sareum said its TYK2 inhibitor autoimmune disease and cancer research programmes advanced with “distinct small molecules” moving into candidate selection for pre-clinical development. CEO Mitchell said he was “pleased” with the progress in this regard.

Rude financial health

The company ended last year with just under £2.2mln in the bank, having raised an additional £700,000 in November.

Investors who backed that funding round at 0.7p a share are now sitting on a decent profit with the shares closing Monday at 0.9p.

As is common for companies at this formative stage of their development, Sareum was loss-making – to the tune of £722,000.

READ: Clinical development programme expands 

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

Graphic of person pointing to different parts of the body
May 14 2018
Paradigm’s share price has increased more than 60% in the last month and it was up more than 12% on Friday.
immunotherapy graphic
September 13 2018
A clinical trial application for the potential cancer treatment is on track to be filed in the current quarter, and that will be followed by patient recruitment towards the end of the year
scientist in lab
September 25 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use